Albert Lowe
Stock Analyst at Craig-Hallum
(2.13)
# 2,910
Out of 5,117 analysts
10
Total ratings
40%
Success rate
3.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $88.44 | +97.87% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $18.43 | +171.30% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.62 | +548.09% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $2.13 | +181.69% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.86 | +1,531.89% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.74 | +194.12% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.84 | +181.69% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.69 | +136.69% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.22 | +391.80% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $88.44
Upside: +97.87%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $18.43
Upside: +171.30%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.62
Upside: +548.09%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $2.13
Upside: +181.69%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.86
Upside: +1,531.89%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.74
Upside: +194.12%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.84
Upside: +181.69%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.69
Upside: +136.69%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.22
Upside: +391.80%